RT Journal Article
T1 Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea.
A1 Masa, Juan F
A1 Corral, Jaime
A1 Caballero, Candela
A1 Barrot, Emilia
A1 Terán-Santos, Joaquin
A1 Alonso-Álvarez, Maria L
A1 Gomez-Garcia, Teresa
A1 González, Mónica
A1 López-Martín, Soledad
A1 De Lucas, Pilar
A1 Marin, José M
A1 Marti, Sergi
A1 Díaz-Cambriles, Trinidad
A1 Chiner, Eusebi
A1 Egea, Carlos
A1 Miranda, Erika
A1 Mokhlesi, Babak
A1 Spanish Sleep Network, 
A1 García-Ledesma, Estefanía
A1 Sánchez-Quiroga, M-Ángeles
A1 Ordax, Estrella
A1 González-Mangado, Nicolás
A1 Troncoso, Maria F
A1 Martinez-Martinez, Maria-Ángeles
A1 Cantalejo, Olga
A1 Ojeda, Elena
A1 Carrizo, Santiago J
A1 Gallego, Begoña
A1 Pallero, Mercedes
A1 Ramón, M Antonia
A1 Díaz-de-Atauri, Josefa
A1 Muñoz-Méndez, Jesús
A1 Senent, Cristina
A1 Sancho-Chust, Jose N
A1 Ribas-Solís, Francisco J
A1 Romero, Auxiliadora
A1 Benítez, José M
A1 Sanchez-Gómez, Jesús
A1 Golpe, Rafael
A1 Santiago-Recuerda, Ana
A1 Gomez, Silvia
A1 Bengoa, Mónica
K1 Non invasive ventilation
K1 Sleep apnoea
AB Non-invasive ventilation (NIV) is an effective form of treatment in patients with obesity hypoventilation syndrome (OHS) who have concomitant severe obstructive sleep apnoea (OSA). However, there is a paucity of evidence on the efficacy of NIV in patients with OHS without severe OSA. We performed a multicentre randomised clinical trial to determine the comparative efficacy of NIV versus lifestyle modification (control group) using daytime arterial carbon dioxide tension (PaCO2) as the main outcome measure. Between May 2009 and December 2014 we sequentially screened patients with OHS without severe OSA. Participants were randomised to NIV versus lifestyle modification and were followed for 2 months. Arterial blood gas parameters, clinical symptoms, health-related quality of life assessments, polysomnography, spirometry, 6-min walk distance test, blood pressure measurements and healthcare resource utilisation were evaluated. Statistical analysis was performed using intention-to-treat analysis. A total of 365 patients were screened of whom 58 were excluded. Severe OSA was present in 221 and the remaining 86 patients without severe OSA were randomised. NIV led to a significantly larger improvement in PaCO2 of -6 (95% CI -7.7 to -4.2) mm Hg versus -2.8 (95% CI -4.3 to -1.3) mm Hg, (p NIV is more effective than lifestyle modification in improving daytime PaCO2, sleepiness and polysomnographic parameters. Long-term prospective studies are necessary to determine whether NIV reduces healthcare resource utilisation, cardiovascular events and mortality. NCT01405976; results.
YR 2016
FD 2016-07-12
LK http://hdl.handle.net/10668/10261
UL http://hdl.handle.net/10668/10261
LA en
DS RISalud
RD Mar 14, 2025